Hamster Anti-Mouse CD152-LE/AF

Cat. No.
0.5 mg  
Price (USD)
Clone 1B8
Isotype Hamster (Armenian) IgG1
Isotype Control Hamster IgG-LE/AF
Immunogen Extracellular portion of murine CTLA-4 fused to a murine IgG2a
Specificity Mouse CD152
Alternalte Name(s) CTLA-4, cytotoxic T-lymphocyte protein 4
Description The lymphocyte surface antigen CD152, also known as CTLA-4, is related to the costimulatory molecule CD28 and both molecules share common B7 family counter-receptors. However CD152 is thought to be a negative regulator of T cell activation and may play a role in apoptotic control of T cells. CD152 is relatively conserved among humans, mice, and chickens.
Format/Conjugate LE/AF (Low Endotoxin/Azide Free)
Buffer Formulation Phosphate buffered saline, pH 7.4
Concentration 0.5 mg/mL
Volume 1.0 mL
Storage & Handling 2-8°C; handle under aseptic conditions
Please refer to product specific SDS
Applications for relevant formats of this clone include -
ELISA – Quality tested 2
FLISA – Quality tested
Flow Cytometry – Reported literature 3-11
Stimulation – Reported in literature 1
Recommended Dilutions Please refer to product specific Technical Bulletin
RRID AB_2795295
Gene ID
12477 (Mouse)
Gene Symbol
Ctla4 (Mouse)
Gene Aliases Cd152; Ly-56; Ctla-4
Uniprot ID
P09793 (Mouse)
Uniprot Name
  • FLISA plate was coated with mouse CD152/CTLA-4 and purified/unlabeled Rat IgG1κ. CTLA-4 and purified immunoglobulin were detected with serially diluted Hamster Anti-Mouse CD152-PE (SB Cat. No. 1790-09).

FLISA plate was coated with mouse CD152/CTLA-4 and purified/unlabeled Rat IgG1κ. CTLA-4 and purified immunoglobulin were detected with serially diluted Hamster Anti-Mouse CD152-PE (SB Cat. No. 1790-09).
Related Products (1)
1. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405-13. (Immunogen, Stim)
2. Kimura F, Gotoh M, Tanaka T, Luo Z, Miyazaki J, Uede T, et al. Locally expressed CTLA4-Ig in a pancreatic beta-cell line suppresses accelerated graft rejection response induced by donor-specific transfusion. Diabetologia. 2002;45:831-40. (ELISA)
3. Ben-David H, Sela M, Mozes E. Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis. Proc Natl Acad Sci USA. 2005;102:2028-33. (FC)
4. Sharabi A, Mozes E. The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 cells that are required for the optimal induction and function of Foxp3-expressing CD4 cells. J Immunol. 2008;181:3243-51. (FC)
5. Laronne-Bar-On A, Zipori D, Haran-Ghera N. Increased regulatory versus effector T cell development is associated with thymus atrophy in mouse models of multiple myeloma. J Immunol. 2008;181:3714-24. (FC)
6. Barnes MJ, Krebs P, Harris N, Eidenschenk C, Gonzalez-Quintal R, Arnold CN, et al. Commitment to the regulatory T cell lineage requires CARMA1 in the thymus but not in the periphery. PloS Biol. 2009;7(3):e1000051. (FC)
7. Scalapino KJ, Daikh DI. Suppression of glomerulonephritis in NZB/NZW lupus prone mice by adoptive transfer of ex vivo expanded regulatory T cells. PLoS One. 2009;4(6):e6031. (FC)
8. Wafula PO, Teles A, Schumacher A, Pohl K, Yagita H, Volk H, et al. PD-1 but not CTLA-4 blockage abrogates the protective effect of regulatory T cells in a pregnancy murine model. Am J Reprod Immunol. 2009;62:283-92. (FC)
9. Wang D, Zhou R, Yao Y, Zhu X, Yin Y, Zhao G, et al. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. J Pharmacol Exp Ther. 2010;335:553-61. (FC)
10. Zhang Y, Yao Y, Huang L, Dong N, Yu Y, Sheng Z. The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res. 2011;31:249-57. (FC)
11. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 2013;73:6900-12. (FC)